Related Experiment Video
Updated: May 14, 2026
An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
Published on: July 28, 2012
Cerium oxide-embedded gold nanoparticles loaded with astragaloside IV for bladder cancer therapy
Xiaoyu Zhu1, Xuelai Yin1, Lin Niu2
1Department of Urology, Nanjing Hospital of Traditional Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, 210096, P. R. China.
Abstract:
In bladder cancer, metabolic dysregulation of reactive oxygen species (ROS) promotes malignant transformation through oxidative DNA damage while concurrently activating pro-survival pathways such as NF-κB. To address this, we developed a synergistic therapeutic platform by incorporating gold nanoparticles into cerium oxide nanostructures (Au/CeO₂) with enhanced antioxidant activity, followed by loading with astragaloside IV (Au/CeO₂@As). The core-shell structured Au/CeO₂@As nanocomposites demonstrated remarkable pro-apoptotic effects, exhibiting a 5.11-fold increase in apoptosis induction compared to free astragaloside IV alone. Subsequent cell proliferation assays confirmed the system's ability to effectively inhibit tumor cell migration and proliferation. Mechanistic investigations through qPCR and Western blot analyses revealed that Au/CeO₂@As mediates its antitumor effects through coordinated regulation of the STAT3 and NF-κB signaling pathways, leading to significant tumor cell damage. Importantly, the Au/CeO₂@As nanocomposites did not exhibit significant cytotoxicity while demonstrating excellent therapeutic efficacy. These findings collectively establish Au/CeO₂@As as a highly promising nanotherapeutic candidate for bladder cancer treatment, offering both targeted ROS modulation and specific pathway regulation capabilities.
Insights
A novel nanotherapy, Au/CeO₂@As, effectively targets bladder cancer by modulating reactive oxygen species (ROS) and inhibiting tumor cell growth. This nanoparticle platform shows significant potential for cancer treatment with minimal toxicity.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Metabolic dysregulation of reactive oxygen species (ROS) drives bladder cancer progression via DNA damage and NF-κB activation.
- Targeting ROS and pro-survival pathways is crucial for effective bladder cancer therapy.
Purpose of the Study:
- To develop and evaluate a novel nanotherapeutic platform, Au/CeO₂@As, for bladder cancer treatment.
- To investigate the synergistic effects of gold nanoparticles, cerium oxide nanostructures, and astragaloside IV on bladder cancer cells.
Main Methods:
- Synthesis of core-shell Au/CeO₂@As nanocomposites.
- Assessment of apoptosis induction, cell proliferation, and migration inhibition.
- Analysis of STAT3 and NF-κB signaling pathway regulation using qPCR and Western blot.
Main Results:
- Au/CeO₂@As nanocomposites significantly increased apoptosis (5.11-fold) compared to astragaloside IV alone.
- The nanotherapy effectively inhibited bladder tumor cell migration and proliferation.
- Au/CeO₂@As demonstrated coordinated regulation of STAT3 and NF-κB pathways, leading to tumor cell damage.
- The nanocomposites exhibited excellent therapeutic efficacy with no significant cytotoxicity.
Conclusions:
- Au/CeO₂@As represents a promising nanotherapeutic agent for bladder cancer.
- The platform offers targeted ROS modulation and specific regulation of key cancer signaling pathways.
- This synergistic approach holds potential for improved bladder cancer treatment strategies.
